Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

topotecan/atrophy

Link salvestatakse lõikelauale
Leht 1 alates 17 tulemused

Intratumoral infusion of topotecan prolongs survival in the nude rat intracranial U87 human glioma model.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Topotecan is a topoisomerase (topo) I inhibitor with promising activity in preclinical studies. We hypothesized that low-dose intratumoral delivery of topotecan would be highly effective for gliomas. Human glioma cell lines (U87, U138 and U373) displayed different sensitivities to topotecan (IC50
OBJECTIVE To determine intravitreal and plasma concentrations and retinal toxicity after transcorneal intravitreal injection of 1 μg and 2 μg of topotecan (Hycamtin). METHODS Twelve healthy albino rabbits were included in this in vivo experiment. Six anesthetized albino rabbits received a single

Neutrophilic eccrine hidradenitis secondary to topotecan.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND Neutrophilic eccrine hidradenitis (NEH) is a self-restricted inflammatory condition, usually secondary to chemotherapeutic agents and less frequently to other drugs such as zidovudine or various infections. NEH clinical features include erythematous, occasionally painful nodules and
Anticancer agents may cause side effects and some of which may be dose dependant. It is important for clinicians to see the effects on tissues histopathologically. The aim of this study was to investigate the effects of topotecan (hycamtin), a topoisomerase I inhibiting anticancer agent, on nasal,
BACKGROUND A recent phase III trial compared the efficacy of cisplatin-topotecan (a topoisomerase I inhibitor) followed by carboplatin-paclitaxel (Arm 1) versus paclitaxel-carboplatin (Arm 2) in women with newly diagnosed stage IIB or greater ovarian cancer. There was a significantly lower response
OBJECTIVE Topotecan, administered intravenously, is active in small-cell lung cancer (SCLC). In this study, the comparability of oral topotecan to IV topotecan was investigated. METHODS Patients with SCLC that had relapsed 90 days or more after cessation of initial chemotherapy were randomized to

HIF inhibitor topotecan has a neuroprotective effect in a murine retinal ischemia-reperfusion model.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The therapeutic approach for retinal ganglion cell (RGC) degeneration has not been fully established. Recently, it has been reported that hypoxia-inducible factor (HIF) may be involved with retinal neurodegeneration. In this study, we investigated neuroprotective effects of a HIF
OBJECTIVE For patients with small-cell lung cancer (SCLC), further chemotherapy is routinely considered at relapse after first-line therapy. However, proof of clinical benefit has not been documented. METHODS This study randomly assigned patients with relapsed SCLC not considered as candidates for

Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND Symptomatic brain metastases occur in approximately 10-15% of patients suffering from breast cancer and are linked to a clear deterioration of the patient's condition. Although radiotherapy is recommended as a primary therapy, the optimal management remains controversial. To evaluate the
BACKGROUND GOG 240 was a practice-changing randomised phase 3 trial that concluded that chemotherapy plus bevacizumab for advanced cervical cancer significantly improves overall and progression-free survival, and the proportion of patients achieving an overall objective response, compared with

Neoplastic meningitis: diagnosis and treatment considerations.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Neoplastic meningitis is an increasingly recognized complication of advanced metastatic cancer and, if left undiagnosed or untreated, is characterized by rapid neurologic deterioration and death. Thus, the diagnosis and treatment of neoplastic meningitis present challenges for the clinical

Optimal management strategies for rhabdomyosarcoma in children.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Rhabdomyosarcoma is the most common sarcoma of childhood. Fortunately, the goal of cure is realistic for the majority of patients with localized tumors. However, management of these patients remains challenging. The fact that the tumor arises in a wide variety of primary sites, some of which are

Potential novel role of bevacizumab in glioblastoma and cervical cancer.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The VEGF-A binding monoclonal antibody bevacizumab is a widely prescribed angiogenesis inhibitor and indicated for many types of cancer. As shown by three randomized phase 3 trials recently published in the New England Journal of Medicine, novel indications for this drug are still being explored. In
To use our intra-arterial chemotherapy (IAC) rabbit model to assess the impact of IAC procedure, drug, dose, and choice of technique on ocular structure and function, to study the nature and etiology of IAC toxicity, and to compare to observations in

TDP1 facilitates chromosomal single-strand break repair in neurons and is neuroprotective in vivo.

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Defective Tyrosyl-DNA phosphodiesterase 1 (TDP1) can cause spinocerebellar ataxia with axonal neuropathy (SCAN1), a neurodegenerative syndrome associated with marked cerebellar atrophy and peripheral neuropathy. Although SCAN1 lymphoblastoid cells show pronounced defects in the repair of chromosomal
Liitu meie
facebooki lehega

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus

  • Töötab 55 keeles
  • Taimsed ravimid, mida toetab teadus
  • Maitsetaimede äratundmine pildi järgi
  • Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
  • Lugege oma otsinguga seotud teaduspublikatsioone
  • Otsige ravimtaimi nende mõju järgi
  • Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega

Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel

Google Play badgeApp Store badge